Main Products:
Baloxavir marboxil,
Baloxavir,
7,8-difluorodibenzo[b,e]thiepin-11(6H)-one,
Introduct:
Heading (Nanjing) Pharmtechnologies Co., Ltd. was established in February 2013. We are a rapidly developing national high-tech enterprise specializing in the development of unique pharmaceutical products, recognized as a nurtured unicorn company. We integrate research, production, and sales into a closed-loop system, with our products primarily sold to large central state-owned pharmaceutical groups. Adhering to the principles of "innovation, efficiency, and win-win," the company provides global pharmaceutical enterprises with the development and production of chiral small molecule active drugs, as well as the research, production, and sales of our own branded products.
The company headquarters is located in the scenic and high-tech concentrated Nanjing Jiangbei New Area. We currently have 4,000 square meters of R&D and office space. In accordance with international standards, we have established the Jiangsu Provincial Engineering Research Center for Chiral Small Molecule Drugs. Additionally, we possess a quality testing center equipped with LC-MS, gas chromatography, liquid chromatography, and other instruments with a total value exceeding 20 million RMB. To meet development needs, in 2018, the company fully acquired an API production base and has achieved industrialization of our own branded products. In 2019, a new specialized active ingredient production base was constructed and successfully put into operation in 2021.
Capital and hardware are prerequisites, but talent is the core of a company's competitiveness in the market. Our company boasts a top-tier scientific research management team with international experience, primarily educated in the United States, and has built a high-quality team of professionals in management, R&D, production, and sales. The group's chief scientist has accumulated over 20 years of practical experience in world-leading pharmaceutical companies, with extensive expertise in new drug research and development, process route design, optimization, and industrialization. Recognized as a high-end overseas talent introduced by Nanjing, the company also employs several experts in the biomedical research field from both domestic and international backgrounds as technical consultants.
Since its establishment, the company has received numerous qualifications and honors:
• 2015: Jiangsu Provincial Private Sci-Tech Enterprise;
• 2016: National High-Tech Enterprise;
• 2017: Nanjing Municipal Engineering Technology Research Center;
• 2018: Jiangbei New Area "Lingque Enterprise," Jiangsu Provincial Sci-Tech Service Backbone Institution, Jiangsu Provincial Enterprise Credit Management Standardization Enterprise, Industrial Enterprise Above Designated Size;
• 2019: Nanjing Municipal "Gazelle Enterprise," Nanjing Municipal Credit Management Demonstration Enterprise, Nanjing Municipal Enterprise Technology Center, Nanjing Municipal "Specialized, Refined, Unique, and New" Enterprise;
• 2020: Nanjing Municipal Postdoctoral Innovation Practice Base;
• 2021: Nanjing Municipal "Nurtured Unicorn Enterprise," Jiangsu Provincial Engineering Research Center for Chiral Small Molecule Drugs, Jiangsu Provincial "Specialized, Refined, Unique, and New" Little Giant Enterprise, Jiangsu Provincial Healthy Enterprise;
• 2022: National Level "Specialized, Refined, Unique, and New" Little Giant Enterprise.
Looking ahead, as a company in a nationally supported high-tech industry, Heading will leverage its strong R&D capabilities, innovative product design, leading production technology, and continuously improving quality system to strive to become an innovator and leader in the field of self-branded biomedical products!,